Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project

Author:

Lange BeritORCID,Jaeger Veronika KORCID,Harries ManuelaORCID,Rücker Viktoria,Streeck Hendrik,Blaschke Sabine,Petersmann AstridORCID,Toepfner NicoleORCID,Nauck MatthiasORCID,Hassenstein Max JORCID,Dreier Maren,Von Holt Isabell,Budde AxelORCID,Bartz AntoniaORCID,Ortmann JuliaORCID,Kurosinski Marc-André,Berner ReinhardORCID,Borsche MaxORCID,Brandhorst Gunnar,Brinkmann MelanieORCID,Budde Kathrin,Deckena Marek,Engels Geraldine,Fenzlaff Marc,Härtel Christoph,Hovardovska OlgaORCID,Katalinic AlexanderORCID,Kehl Katja,Kohls MirjamORCID,Krüger Stefan,Lieb Wolfgang,Meyer-Schlinkmann Kristin MORCID,Pischon TobiasORCID,Rosenkranz Daniel,Rübsamen Nicole,Rupp Jan,Schäfer Christian,Schattschneider Mario,Schlegtendal AnneORCID,Schlinkert Simon,Schmidbauer Lena,Schulze-Wundling Kai,Störk Stefan,Tiemann Carsten,Völzke Henry,Winter Theresa,Klein Christine,Liese Johannes,Brinkmann FolkeORCID,Ottensmeyer Patrick FORCID,Reese Jens-PeterORCID,Heuschmann PeterORCID,Karch AndréORCID

Abstract

AbstractDespite the need to generate valid and reliable estimates of protection against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real-time.In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n=33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses (“confirmed exposures”). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest.Most participants were seropositive against the spike antigen; 37% of the participants ≥79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4%-28% of participants having less than three confirmed exposures.Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.

Publisher

Cold Spring Harbor Laboratory

Reference27 articles.

1. Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany—A Blind Spot in Epidemiology?;Infectious Disease Reports,2021

2. High Seroprevalence of SARS-CoV-2 in Preschool Children in July 2022;Dtsch Arztebl Int,2022

3. SARS-CoV-2 Seroprevalence in Germany: A Population-Based Sequential Study in Seven Regions;Deutsches ärzteblatt international,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3